World's Best Scientists 2026 revealed!
Xavier Thomas

Xavier Thomas

D-Index & Metrics

Medicine

D-Index
90
Citations
31079
World Ranking
12172
National Ranking
6242

Overview

Xavier Thomas is affiliated with Lyon College in the United States and has a substantial body of work primarily within the medical sciences. Their research output is concentrated in the field of Medicine, with 196 publications. Within this broad area, the main subfields include Hematology, Molecular Biology, Genetics, Public Health, Environmental and Occupational Health, and Oncology.

Their research extensively covers topics related to leukemia and related hematological conditions. The main topics of Thomas's work include:

  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Histone Deacetylase Inhibitors Research
  • CAR-T cell therapy research
  • Protein Degradation and Inhibitors

Frequent collaborators in their publications comprise several researchers with repeated co-authorship, emphasizing collaborative efforts in the field. These co-authors include Christian Récher, Hervé Dombret, Arnaud Pigneux, Emmanuel Raffoux, and Nicolas Boissel.

Thomas has published multiple papers in a variety of scientific journals, with a notable concentration in venues such as Blood and Blood Advances. Other frequent publication venues include Clinical Lymphoma Myeloma & Leukemia, Leukemia, and Oncology and Therapy.

Significant recent papers authored or co-authored by Thomas demonstrate a focus on clinical and therapeutic studies in acute myeloid leukemia (AML) and related areas. Some of these include:

  • "Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML" (2023, Blood Advances)
  • "Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort" (2021, Blood Advances)
  • "Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial" (2022, Blood)
  • "Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients" (2021, Nature Communications)
  • "Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results" (2020, Blood Advances)

The research activities reflect a blend of clinical trials, genetic and molecular studies, as well as investigations into the microbiota's role in leukemia treatment outcomes, indicating multidisciplinary approaches to addressing hematological malignancies.

Best Publications

  • Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

    Hagop M Kantarjian;Anthony Stein;Nicola Gökbuget;Adele K. Fielding

  • Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

    Hagop M. Kantarjian;Xavier G. Thomas;Anna Dmoszynska;Agnieszka Wierzbowska

  • Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

    Sylvie Castaigne;Cécile Pautas;Christine Terré;Emmanuel Raffoux

  • Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials

    Nicolas Boissel;Marie-Françoise Auclerc;Véronique Lhéritier;Yves Perel

  • Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study

    Françoise Huguet;Thibaut Leguay;Emmanuel Raffoux;Xavier Thomas

  • OUTCOME OF TREATMENT IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: ANALYSIS OF THE LALA-94 TRIAL

    Xavier Thomas;Jean Michel Boiron;Françoise Huguet;Hervé Dombret

  • Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial.

    Hervé Dombret;Jean Gabert;Jean-Michel Boiron;Françoise Rigal-Huguet

  • Incidence and prognostic impact of c-Kit , FLT3 , and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)

    N Boissel;H Leroy;B Brethon;N Philippe

  • Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

    Céline Berthon;Emmanuel Raffoux;Xavier Thomas;Norbert Vey

  • Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia

    Yves Chalandon;Xavier Thomas;Sandrine Hayette;Jean-Michel Cayuela

  • Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

    Eric Jourdan;Nicolas Boissel;Sylvie Chevret;Eric Delabesse

  • Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.

    Sébastien Maury;Sylvie Chevret;Xavier Thomas;Dominik Heim

  • Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.

    Kheira Beldjord;Sylvie Chevret;Vahid Asnafi;Françoise Huguet

  • Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience

    Lionel Adès;Lionel Adès;Agnes Guerci;Emmanuel Raffoux;Miguel Sanz

  • Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.

    Juliette Lambert;Cécile Pautas;Christine Terré;Emmanuel Raffoux

  • High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

    A.-L. Taksin;O. Legrand;E. Raffoux;T. De Revel

  • Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group

    Marie Balsat;Aline Renneville;Xavier Thomas;Stéphane de Botton

  • NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.

    Vahid Asnafi;Vahid Asnafi;Agnès Buzyn;Sandrine Le Noir;Sandrine Le Noir;Frédéric Baleydier;Frédéric Baleydier

  • Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia

    Nathalie Dhédin;Anne Huynh;Sébastien Maury;Reza Tabrizi

  • Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.

    Nicolas Boissel;Aline Renneville;Valeria Biggio;Nathalie Philippe

Frequent Co-Authors

Claude Preudhomme
Claude Preudhomme University of Lille
Pierre Fenaux
Pierre Fenaux Université Paris Cité
Emmanuel Raffoux
Emmanuel Raffoux Hôpital Saint-Louis
Hervé Dombret
Hervé Dombret Université Paris Cité
Sylvie Castaigne
Sylvie Castaigne Versailles Saint-Quentin-en-Yvelines University
Mauricette Michallet
Mauricette Michallet University of Helsinki
Christian Recher
Christian Recher Federal University of Toulouse Midi-Pyrénées
Nicolas Boissel
Nicolas Boissel Université Paris Cité
Sylvie Chevret
Sylvie Chevret Université Paris Cité
Aline Renneville
Aline Renneville Institut Gustave Roussy

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens a variety of online degree options for those interested in healthcare careers. Prospective nurses may choose rn to bsn online no clinicals programs, which provide flexibility for working RNs to earn their bachelor’s degree without additional on-site requirements.

For nurses aiming to advance to leadership or specialized clinical roles, there are several online dnp programs available that offer accelerated paths to a Doctor of Nursing Practice degree. Budget-conscious students can look for affordable dnp programs, designed to lessen the financial burden while maintaining academic quality.

Additionally, those looking for a quick entry into the nursing field may consider a 6 month lpn program, which provides fast-track training to become a Licensed Practical Nurse. With such a wide array of online health degrees, individuals can find flexible opportunities to match their career goals and schedules.

Best Scientists Citing Xavier Thomas

Trending Scientists